China Pharma Holdings Reports Q1 2026 Revenue Decline and Increased Net Loss

China Pharma Holdings, Inc. reported a revenue of $983,536 for the first quarter of 2026, a decrease of 13.5% from $1,136,287 in the same period of 2025. The company experienced a gross profit of $285,487, a significant turnaround from a gross loss of $136,061 in the prior year, primarily due to reduced costs associated with fully depreciated machinery and equipment. However, the company recorded a net loss of $1,143,148, compared to a net loss of $785,572 in the previous year, reflecting increased general and administrative expenses, particularly from the amortization of newly acquired intangible assets.

In terms of operational changes, China Pharma's total assets increased to $45.14 million as of March 31, 2026, up from $31.00 million at the end of 2025. This growth was largely driven by the acquisition of five new patented technologies, which contributed to a rise in intangible assets from $24.08 million to $38.67 million. The company’s stockholders’ equity also saw a substantial increase, rising to $37.02 million from $22.74 million, following the issuance of 25 million shares for the acquisition of intangible assets.

The company’s operational metrics indicate a shift in product performance, with the CNS Cerebral & Cardio Vascular category generating $510,000 in sales, a 50% increase year-over-year. Conversely, the Anti-Viral/Infection & Respiratory category saw a 43% decline in revenue, dropping to $410,000. This decline was attributed to increased competition and market fluctuations, particularly affecting products like Roxithromycin Dispersible Tablets. The overall revenue mix has shifted, with CNS products now constituting 52.2% of total revenue, up from 29.9% in the previous year.

China Pharma's management has outlined several strategic initiatives to address its financial challenges, including enhancing its sales model and improving accounts receivable collection. The company is also exploring opportunities in the nutrition product sector and plans to optimize its operations to reduce costs. Despite these efforts, the company has raised concerns about its ability to continue as a going concern, given its accumulated deficit of $48.36 million and the reliance on advances from its CEO for working capital. The management's outlook remains cautious, emphasizing the need for successful execution of its strategic plans to improve cash flow and operational stability in the coming months.